Consequently, the development of drugs that specifically target the MEK1 / MAPK1/2 signaling axis has the potential to eliminate the survival of BC cells and hinder the emergence of anti-estrogenic resistance following hormone therapy (Figure 3) 32. The gene discussed is MAP2K1; the disease is breast cancer.